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Original Article

Brentuximab Vedotin with Chemotherapy
for Stage III or IV Hodgkin’s Lymphoma
J.M. Connors, W. Jurczak, D.J. Straus, S.M. Ansell, W.S. Kim, A. Gallamini,
A. Younes, S. Alekseev, Á. Illés, M. Picardi, E. Lech‑Maranda, Y. Oki, T. Feldman,
P. Smolewski, K.J. Savage, N.L. Bartlett, J. Walewski, R. Chen, R. Ramchandren,
P.L. Zinzani, D. Cunningham, A. Rosta, N.C. Josephson, E. Song, J. Sachs, R. Liu,
H.A. Jolin, D. Huebner, and J. Radford, for the ECHELON-1 Study Group*

A BS T R AC T
BACKGROUND

Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved
for relapsed and refractory Hodgkin’s lymphoma.
METHODS

We conducted an open-label, multicenter, randomized phase 3 trial involving patients
with previously untreated stage III or IV classic Hodgkin’s lymphoma, in which 664
were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD). The primary end point was modified progression-free survival (the
time to progression, death, or noncomplete response and use of subsequent anticancer
therapy) as adjudicated by an independent review committee. The key secondary end
point was overall survival.
RESULTS

At a median follow-up of 24.6 months, 2-year modified progression-free survival rates
in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.8 to 85.0)
and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points
(hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI,
0.60 to 0.98; P = 0.04). There were 28 deaths with A+AVD and 39 with ABVD (hazard
ratio for interim overall survival, 0.73 [95% CI, 0.45 to 1.18]; P = 0.20). All secondary
efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the
patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group,
the rate of febrile neutropenia was lower among the 83 patients who received primary
prophylaxis with granulocyte colony-stimulating factor than among those who did not
(11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group
and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who
had peripheral neuropathy had resolution or improvement at the last follow-up visit.
Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during
treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13
in the ABVD group were associated with pulmonary-related toxicity.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to Dr.
Connors at the Department of Medical
Oncology, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada, or at
jconnors@bccancer.bc.ca.
* All ECHELON-1 investigators are listed
in the Supplementary Appendix, available at NEJM.org.
This article was published on December
10, 2017, and last updated on January 26,
2018, at NEJM.org.
N Engl J Med 2018;378:331-44.
DOI: 10.1056/NEJMoa1708984
Copyright © 2017 Massachusetts Medical Society.

CONCLUSIONS

A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage
Hodgkin’s lymphoma, with a 4.9 percentage-point lower combined risk of progression,
death, or noncomplete response and use of subsequent anticancer therapy at 2 years.
(Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.
gov number, NCT01712490; EudraCT number, 2011-005450-60.)
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utcomes for patients with advanced-stage Hodgkin’s lymphoma have
improved dramatically over the past half
century.1 Although regional differences exist, the
most commonly used frontline regimen —
doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) — has not been modified since
its original description in 1975.
Up to 30% of patients with stage III or IV
Hodgkin’s lymphoma harbor refractory disease
or relapse after frontline treatment with ABVD.2‑4
Bleomycin is associated with unpredictable and
sometimes fatal pulmonary toxicity and is often
dropped from later cycles of chemotherapy owing
to pulmonary symptoms.5,6 Recent studies suggest that response-adapted therapy guided by
interim positron-emission tomography (PET) with
18
F-fluorodeoxyglucose can provide a more individualized treatment approach, in which treatment intensity is de-escalated or intensified depending on the early response to treatment.7,8
Efforts are also being made to incorporate new
drugs into established backbone regimens to
improve efficacy and reduce toxicity.9
CD30 is a characteristic surface antigen expressed on Reed–Sternberg cells in classic Hodgkin’s lymphoma.10 Brentuximab vedotin is an antibody–drug conjugate composed of an anti-CD30
monoclonal antibody conjugated by a proteasecleavable linker to the microtubule-disrupting
agent monomethyl auristatin E. Brentuximab
vedotin has been approved for the treatment of
classic Hodgkin’s lymphoma after failure of autologous stem-cell transplantation or after two or
more multiagent chemotherapy regimens in patients who are not candidates for transplantation.
The drug has also been approved as post-transplantation consolidation therapy for patients with
Hodgkin’s lymphoma who are at increased risk
for relapse or progression.11,12
A previous phase 1, dose-escalation trial involving patients with advanced Hodgkin’s lymphoma evaluated the use of frontline brentuximab vedotin combined with either ABVD or
doxorubicin, vinblastine, and dacarbazine (AVD).13
Brentuximab vedotin plus AVD (A+AVD) had an
acceptable side-effect profile and resulted in
complete response in 24 of 25 patients (96%).
Long-term follow-up showed a 5-year failure-free
survival rate of 92% and an overall survival rate
of 100% with A+AVD.14 On the basis of these
findings, ECHELON-1, a large, international,
open-label, randomized, multicenter, phase 3 trial
332
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was conducted to compare A+AVD with ABVD as
frontline therapy in patients with stage III or IV
classic Hodgkin’s lymphoma.

Me thods
Trial Design

Patients were randomly assigned in a 1:1 ratio to
receive A+AVD (1.2 mg of brentuximab vedotin
per kilogram of body weight, 25 mg of doxorubicin per square meter of body-surface area, 6 mg
of vinblastine per square meter, and 375 mg of
dacarbazine per square meter) or ABVD (25 mg
of doxorubicin per square meter, 10 units of
bleomycin per square meter, 6 mg of vinblastine
per square meter, and 375 mg of dacarbazine per
square meter) intravenously on days 1 and 15 of
each 28-day cycle for up to 6 cycles. Brentuximab
vedotin was administered over 30 minutes, starting within approximately 1 hour after completion of AVD. Dose reductions and modifications
are described in Table S1 in the Supplementary
Appendix, available with the full text of this article at NEJM.org. Patients were stratified according to region (Americas vs. Europe vs. Asia) and
International Prognostic Score (IPS) risk group
(low risk vs. intermediate risk vs. high risk). The
IPS ranges from 0 to 7, with a score of 0 or 1 indicating low risk of treatment failure, a score of
2 or 3 intermediate risk, and a score of 4 to 7 high
risk (see Table S2 in the Supplementary Appendix).15 The results of PET conducted at the end of
the second 28-day cycle of treatment (hereafter
referred to as PET2) guided an optional switch
to alternative frontline therapy at the treating
physician’s discretion for patients with a Deauville score of 5. The Deauville score is a 5-point
scale on which higher scores indicate greater
uptake of 18F-fluorodeoxyglucose at involved sites
on PET. A score of 1 indicates no uptake, a score
of 2 uptake at an initial site that is less than or
equal to the uptake at the mediastinum, a score
of 3 uptake at an initial site that is greater than
uptake at the mediastinum but less than or
equal to uptake at the liver, a score of 4 uptake
at an initial site that is moderately increased as
compared with the uptake at the liver, and a
score of 5 markedly increased uptake at any site
or uptake at a new site of disease.16
Oversight

The ECHELON-1 trial was conducted in accordance with regulatory requirements; the proto-
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col (available at NEJM.org) was approved by institutional review boards and ethics committees
at individual sites, and adhered to Good Clinical
Practice guidelines (as defined by the International Conference on Harmonisation). A steering
committee and an independent data and safety
monitoring committee oversaw the conduct of
the trial, and all the patients provided written
informed consent.
The trial was designed by a committee consisting of six authors plus representatives of the
sponsors, Millennium Pharmaceuticals and Seattle
Genetics. Data were collected and trial procedures were overseen by trial investigators. Data
were verified by the sponsors, analyzed by sponsor statisticians, and interpreted by academic
authors and sponsor representatives. The manuscript was prepared by the authors with the assistance of a medical writer funded by the sponsors. All the authors had full access to the data,
vouch for the completeness and accuracy of the
data and adherence of the trial to the protocol,
and had final responsibility for the manuscript
content and the decision to submit the manuscript for publication.
Patients

Patients were 18 years of age or older and had
histologically confirmed advanced classic Hodgkin’s lymphoma (Ann Arbor stage III or IV, as
determined on a 4-point scale, with higher
stages indicating more widespread disease),17 according to the World Health Organization classification system.18 Patients who had not been
previously treated with systemic chemotherapy
or radiotherapy were eligible. Patients were required to have an Eastern Cooperative Oncology
Group performance status of 0, 1, or 2 (on a scale
of 0 to 5, with higher scores indicating greater
disability)19; satisfactory absolute neutrophil counts
(≥1500 per cubic millimeter), platelet counts
(≥75,000 per cubic millimeter), and hemoglobin
levels (≥8 g per deciliter) (with the exception of
patients with involvement of the marrow); satisfactory levels of markers of liver function (total
bilirubin level, <1.5 times the upper limit of
normal [with the exception of patients with Gilbert’s syndrome] and alanine aminotransferase
or aspartate aminotransferase levels, <3 times
the upper limit of normal [with the exception of
patients with involvement of the liver]); and satisfactory levels of markers of kidney function
(serum creatinine level, <2.0 mg per deciliter
n engl j med 378;4

[177 μmol per liter]; creatinine clearance or calculated creatinine clearance, >40 ml per minute;
or both). Patients with nodular lymphocytepredominant Hodgkin’s lymphoma were ineligible, as were those with peripheral sensory or
motor neuropathy, a positive pregnancy test,
known cerebral or meningeal disease, any evidence of residual disease from another cancer,
diagnosis of another cancer within 3 years before the first dose, or any clinically relevant
cardiovascular conditions.
End Points

The primary end point was modified progressionfree survival, defined as time to disease progression, death, or modified progression (with the
latter defined as evidence of noncomplete response after completion of frontline therapy according to review by an independent committee,
followed by subsequent anticancer therapy). This
end point was chosen specifically to evaluate the
effectiveness of the primary chemotherapy and
encompasses three possible outcomes, each of
which represents a failure of the primary chemotherapy to eliminate Hodgkin’s lymphoma: documented progression20 at any time after initiation
of primary chemotherapy, death from any cause,
and detection of a response that was less than
complete at the end of primary chemotherapy
(Deauville score of 3, 4, or 5 on a PET scan), followed by the delivery of subsequent anticancer
therapy. The latter outcome was considered to be
an event only if noncomplete response was confirmed during review by an independent committee, whose members were unaware of group
assignments, and was followed by the delivery of
subsequent anticancer treatment that was not
specified in the protocol. Additional justifications for, and explanation of, this choice of primary end point are provided in the Supplementary
Appendix. Timing of the modified progression
event was the date on which the first PET scan
was obtained after completion of frontline therapy, showing the absence of complete response.
In the absence of disease progression, a switch
to an alternative frontline therapy before completion of primary chemotherapy with the randomized regimen was not considered to be an
event.
The key secondary end point was overall survival, defined as the time from randomization to
death from any cause. Other secondary and exploratory end points are described in the protocol.
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Assessments

Response and progression were evaluated in accordance with the Revised Response Criteria for
Malignant Lymphoma.20 Computed tomographic scans were obtained at screening, at the end
of cycle 2, after administration of the last dose of
frontline therapy, and during the follow-up
period (every 3 months for the first year and
every 6 months thereafter). PET scans were obtained at screening, at the end of cycle 2, and at
the end of treatment. Safety outcomes were the
incidence of adverse events (defined according to
the Medical Dictionary for Regulatory Activities
[MedDRA], version 19.0, and the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.03) and changes in vital
signs and laboratory test results.

334

R e sult s
Patients

From November 19, 2012, through January 13,
2016, a total of 1334 patients at 218 sites in 21
countries were randomly assigned to receive
A+AVD (664 patients) or ABVD (670 patients)
(intention-to-treat population) (Fig. S1 in the
Supplementary Appendix). Overall, 58% of the
patients were men, 64% had stage IV disease,
62% had extranodal involvement at diagnosis,
59% had B symptoms (i.e., weight loss, night
sweats, and fever), and the median age was 36
years (34% of patients were ≥45 years of age).
Baseline characteristics were generally well balanced between the two groups (Table 1, and
Table S3 in the Supplementary Appendix).

Statistical Analysis

Efficacy

According to statistical calculations, an estimated
260 modified progression-free survival events
would give the trial 90% power to detect a hazard ratio for disease progression, death, or modified progression of 0.67 at a one-sided significance level of 0.025. The trial was powered on
the following assumption: a 2-year modified
progression-free survival of 81% for patients in
the A+AVD group and 73% for patients in the
ABVD group. Randomization of approximately
1240 patients was planned to achieve (with 95%
probability) 260 modified progression-free survival events. The primary end point was summarized with the use of the Kaplan–Meier method
and evaluated with the use of a stratified logrank test. A stratified Cox regression model was
used to estimate the hazard ratio and the 95%
confidence interval for the treatment effect. The
stratification factors included region and IPS
risk group at baseline. The interim analysis for
overall survival was to be performed if the result
of the primary analysis was statistically significant. The final overall survival analysis will be
performed after 112 deaths have occurred. Overall type I error for the overall survival analysis
will be controlled with the use of the O’Brien–
Fleming method with the Lan–DeMets alpha
spending function.
All efficacy evaluations were performed in
the intention-to-treat population unless otherwise
specified. Safety was analyzed in patients who
received at least one dose of the trial drug (the
safety population).

After a median follow-up of 24.6 months (range,
0 to 49.0), the rate of the primary end point of
independently determined modified progressionfree survival was significantly higher in the
A+AVD group than in the ABVD group (2-year
modified progression-free survival rate, 82.1%
[95% confidence interval {CI}, 78.8 to 85.0] vs.
77.2% [95% CI, 73.7 to 80.4]; hazard ratio for
progression, death, or modified progression, 0.77
[95% CI, 0.60 to 0.98]; P = 0.04), corresponding
to a 23% risk reduction (Fig. 1A). Events of progression, death, or modified progression occurred in 117 patients in the A+AVD group and
in 146 patients in the ABVD group; disease
progression occurred in 90 and 102 patients,
respectively; death from any cause in 18 and 22
patients, respectively, and receipt of subsequent
anticancer therapy after failure to achieve a complete response at the completion of frontline
therapy (modified progression) in 9 and 22 patients, respectively (Table 2). The majority (71%)
of these subsequent anticancer therapies consisted of salvage chemotherapy (7 of 9 patients
in the A+AVD group and 15 of 22 patients in the
ABVD group), with radiotherapy given to the
remainder of patients in both groups (Table S4
in the Supplementary Appendix). Modified progression events assigned because of an end-oftreatment PET scan and subsequent treatment
were predominantly associated with a Deauville
score of 4 or 5 (a score of 3 was recorded in 7 of
31 patients [23%], a score of 4 in 10 of 31 patients
[32%], and a score of 5 in 14 of 31 patients
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Table 1. Patient Demographic and Clinical Characteristics at Baseline (Intention-to-Treat Population).*
Characteristic

A+AVD
(N = 664)

ABVD
(N = 670)

Total
(N = 1334)

Male sex ― no. (%)

378 (57)

398 (59)

776 (58)

Age — yr
Median

35

37

36

Range

18–82

18–83

18–83

<45 yr

451 (68)

423 (63)

874 (66)

Age categories ― no. (%)
45–59 yr

129 (19)

145 (22)

274 (21)

60–64 yr

24 (4)

40 (6)

64 (5)

≥65 yr

60 (9)

62 (9)

122 (9)

Regions ― no. (%)
Americas

261 (39)

262 (39)

523 (39)

Europe

333 (50)

336 (50)

669 (50)

70 (11)

72 (11)

142 (11)

1 (<1)

0

Asia
Ann Arbor stage at initial diagnosis ― no. (%)†
Stage II‡

1 (<1)

Stage III

237 (36)

246 (37)

483 (36)

Stage IV

425 (64)

421 (63)

846 (64)

1 (<1)

3 (<1)

4 (<1)

Not applicable, unknown, or missing
International Prognostic Score ― no. (%)§
0 or 1

141 (21)

141 (21)

282 (21)

2 or 3

354 (53)

351 (52)

705 (53)

4 to 7

169 (25)

178 (27)

347 (26)

ECOG performance status ― no. (%)¶
0

376 (57)

378 (57)

754 (57)

1

260 (39)

263 (39)

523 (39)

2

28 (4)

27 (4)

55 (4)

Not obtained or missing

0

2 (<1)

2 (<1)

Extranodal involvement at diagnosis ― no. (%)
Yes
1 extranodal site
>1 extranodal sites
No
Unknown or missing
Patients with any B symptom ― no. (%)‖

411 (62)

416 (62)

827 (62)

217 (33)

223 (33)

440 (33)

194 (29)

193 (29)

387 (29)

217 (33)

228 (34)

445 (33)

36 (5)

26 (4)

62 (5)

400 (60)

381 (57)

781 (59)

*	A full description of patient demographics and clinical characteristics at baseline can be found in Table S3 in the
Supplementary Appendix. Percentages may not total 100 because of rounding. A+AVD denotes brentuximab vedotin
plus doxorubicin, vinblastine, dacarbazine, and ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine.
†	The Ann Arbor staging system ranges from I to IV, with higher stages indicating more widespread disease.
‡	Patients in this category had a major protocol violation.
§	The International Prognostic Score ranges from 0 to 7, with higher scores indicating increased risk of treatment failure.
Scores of 0 to 1 denote low risk, scores of 2 to 3 intermediate risk, and scores of 4 to 7 high risk.
¶	Values for Eastern Cooperative Oncology Group (ECOG) performance status range from 0 to 5, with higher scores indicating greater disability.
‖	B symptoms consist of night sweats, unexplained fever (temperature >38°C), or loss of more than 10% of body weight.
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A Modified Progression-free Survival as Assessed by Independent Review Committee
1.0

Probability of Modified Progression-free Survival

0.9
A+AVD

0.8
ABVD

0.7
0.6

A+AVD, censored

0.5

ABVD, censored
0.4
Hazard ratio for progression, death, or modified progression, 0.77 (95% CI, 0.60–0.98)
P=0.04 by stratified log-rank test
No. of events: A+AVD, 117; ABVD, 146

0.3
0.2

Reasons Leading to Event

0.1

Disease progression
Death from any cause
Subsequent anticancer therapy when complete response
not achieved at completion of frontline therapy

0.0

0

2

4

6

8

A+AVD
(N=117)

ABVD
(N=146)

90
18
9

102
22
22

10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52

Months since Randomization
No. at Risk
A+AVD
ABVD

664 637 623 600 541 528 513 493 463 439 347 328 309 196 185 169 96 85 77 26 24 21
670 636 626 593 521 490 474 459 432 413 326 306 292 177 164 153 76 66 62 16 13 12

4
1

4
1

4
1

0
0

0
0

B Modified Progression-free Survival as Assessed by Investigator
1.0

Probability of Modified Progression-free Survival

0.9
A+AVD

0.8
0.7

ABVD

0.6
A+AVD, censored
ABVD, censored

0.5

Hazard ratio for progression, death, or modified progression, 0.72 (95% CI, 0.57–0.91)
P=0.006 by stratified log-rank test
No. of events: A+AVD, 123; ABVD, 164

0.4
0.3
0.2

Reasons Leading to Event

0.1

Disease progression
Death from any cause
Subsequent anticancer therapy when complete response
not achieved at completion of frontline therapy

0.0

0

2

4

6

8

A+AVD
(N=123)

ABVD
(N=164)

73
15
35

103
22
39

10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52

Months since Randomization
No. at Risk
A+AVD
ABVD

336

664 640 626 604 536 523 514 495 468 448 360 340 324 202 191 175 99 87 79 27 24 21
670 636 628 594 513 488 474 463 439 424 340 315 297 182 167 157 78 69 62 16 13 12
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Table 2. Summary of Modified Progression-free Survival According to the Independent Review Committee and Concordance
with Events Noted by Trial Investigators (Intention-to-Treat Population).
A+AVD
(N = 664)

Events

ABVD
(N = 670)

Total
(N = 1334)

117

146

263

Progression — no./total no. (%)

90/117 (77)

102/146 (70)

192/263 (73)

Death — no./total no. (%)

18/117 (15)

22/146 (15)

40/263 (15)

9/117 (8)

22/146 (15)

31/263 (12)

Patients with events per independent review committee — no.

Positive PET scan and subsequent treatment — no./total no. (%)*
Patients with positive PET scan and subsequent treatment — no.
Salvage chemotherapy — no./total no. (%)†

9

22

31

7/9 (78)

15/22 (68)

22/31 (71)

Met criteria for PFS event
PFS event or modified event reported by investigator — no.

7

15

22

PFS event reported by investigator — no./total no. (%)

7/7 (100)

13/15 (87)

20/22 (91)

PFS event reported by independent review committee
— no./total no. (%)

2/7 (29)

3/15 (20)

5/22 (23)

1

0

0

0

2

0

0

0

3

0

2/15 (13)

2/22 (9)

4

3/7 (43)

4/15 (27)

7/22 (32)

5

4/7 (57)

9/15 (60)

13/22 (59)

2/9 (22)

7/22 (32)

9/31 (29)

Deauville score at end of treatment — no./total no. (%)‡

Radiation — no./total no. (%)
Met criteria for PFS event
PFS event or modified event reported by investigator — no.

2

7

9

PFS event reported by investigator — no./total no. (%)

0

1/7 (14)

1/9 (11)

PFS event reported by independent review committee
— no./total no. (%)

0

1/7 (14)

1/9 (11)

1

0

0

0

2

0

0

0

3

2/2 (100)

3/7 (43)

5/9 (56)

4

0

3/7 (43)

3/9 (33)

5

0

1/7 (14)

1/9 (11)

Deauville score at end of treatment — no./total no. (%)‡

*	There were 58 patients at risk for a modified progression event (end-of-treatment Deauville score ≥3 and no progressive
disease at the end of treatment): 19 in the group receiving A+AVD versus 39 in the group receiving ABVD. However, only
9 patients in the A+AVD group and 22 patients in the ABVD group actually had a modified progression event because they
received subsequent treatment. PET denotes positron-emission tomography, and PFS progression-free survival.
†	Salvage chemotherapy included the terms chemotherapy, high-dose chemotherapy plus transplantation, and immunotherapy according to medical review.
‡	The Deauville score is a 5-point scale on which higher scores indicate greater uptake of 18F-fluorodeoxyglucose at involved sites on PET. A score of 1 indicates no uptake, a score of 2 uptake at an initial site that is less than or equal to
the uptake at the mediastinum, a score of 3 uptake at an initial site that is greater than uptake at the mediastinum but
less than or equal to uptake at the liver, a score of 4 uptake at an initial site that is moderately increased as compared
with uptake at the liver, and a score of 5 markedly increased uptake at any site or uptake at a new site of disease. The
absence of complete response at the end of primary chemotherapy was defined as a Deauville score of 3, 4, or 5.
Figure 1 (facing page). Modified Progression-free Survival in the Intention-to-Treat Population.
Panel A shows Kaplan–Meier estimates of modified progression-free survival, by treatment group, according to the independent review
committee. The hazard ratio for treatment with A+AVD versus ABVD and the 95% confidence intervals (CIs) were based on a stratified
Cox proportional-hazards regression model, with treatment as the explanatory variable. Stratification factors included region and International Prognostic Score risk group at baseline. Panel B shows Kaplan–Meier estimates of modified progression-free survival, by treatment group, according to investigators. In Panels A and B, circles indicate censored data. A+AVD denotes brentuximab vedotin plus
doxorubicin, vinblastine, and dacarbazine, and ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine.
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Table 3. Summary of Responses in the Intention-to-Treat Population.
Measure

A+AVD
(N = 664)

ABVD
(N = 670)

Difference (95% CI)*

Complete response at end of randomized regimen†

488 (73)

472 (70)

3.0 (−2.3 to 8.4)

Overall response at end of randomized regimen‡

569 (86)

553 (83)

3.2 (−2.2 to 8.6)

Complete response at end of frontline therapy§

488 (73)

474 (71)

2.7 (−2.6 to 8.1)

≤3 After completion of frontline therapy

570 (86)

551 (82)

3.6 (−1.8 to 9.0)

≤2 After completion of frontline therapy

563 (85)

537 (80)

4.6 (−0.8 to 10.0)

no. (%)

%

Deauville score¶

Summary at cycle 2
1

435 (66)

414 (62)

2

131 (20)

133 (20)

3

22 (3)

30 (4)

4

26 (4)

28 (4)

5

21 (3)

30 (4)

Unavailable

29 (4)

35 (5)

1

444 (67)

425 (63)

2

119 (18)

112 (17)

Summary after completion of primary chemotherapy

3

7 (1)

14 (2)

4

12 (2)

20 (3)

5

46 (7)

45 (7)

Unavailable

36 (5)

54 (8)

*	Confidence intervals (CIs) were calculated from the exact confidence interval, have not been adjusted for the multiple
comparisons, and should not be used for definitive comparisons.
†	Complete response at the end of the randomized regimen is defined as the proportion of patients who had complete
response20 at the end of treatment with either regimen (A+AVD or ABVD).
‡	Overall response at the end of the randomized regimen is defined as the proportion of patients who had complete or
partial response20 at the end of treatment with either regimen (A+AVD or ABVD).
§	Complete response at the end of frontline therapy is defined as the proportion of patients who had complete response
after the completion of either the randomized regimen (A+AVD or ABVD) or alternate frontline therapy.
¶	The Deauville score is a 5-point scale on which higher scores indicate greater uptake of 18F-fluorodeoxyglucose at involved sites on PET. A score of 1 indicates no uptake, a score of 2 uptake at an initial site that is less than or equal to
the uptake at the mediastinum, a score of 3 uptake at an initial site that is greater than uptake at the mediastinum but
less than or equal to uptake at the liver, a score of 4 uptake at an initial site that is moderately increased as compared
with uptake at the liver, and a score of 5 markedly increased uptake at any site or uptake at a new site of disease. The
absence of complete response at the end of primary chemotherapy was defined as a Deauville score of 3, 4, or 5.

[45%]); these events also met the criteria for a
progression event according to investigator assessment. Of note, only 7 of the 21 patients with
a Deauville score of 3 on the end-of-treatment
PET scan went on to receive additional therapy
and were therefore determined to have had a
modified progression event (2 patients in the
A+AVD group and 5 patients in the ABVD group;
Tables 2 and 3).
According to investigator assessment, the
2-year modified progression-free survival rate was
81.0% (95% CI, 77.6 to 83.9) with the A+AVD
regimen versus 74.4% (95% CI, 70.7 to 77.7) with
the ABVD regimen, corresponding to a 28%
338
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lower overall risk of an event among patients
treated with A+AVD than among those treated
with ABVD (hazard ratio for progression, death,
or modified progression, 0.72; 95% CI, 0.57 to
0.91; P = 0.006) (Fig. 1B). There was 91% concordance between independent review and investigator determination of a modified progressionfree survival event.
Prespecified subgroup analyses of modified
progression-free survival showed a hazard ratio
of less than 1 for the A+AVD regimen versus the
ABVD regimen in the majority of subgroups
(Fig. 2). Certain subgroups of patients appeared
to benefit more with A+AVD than with ABVD.
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Subgroup

A+AVD

ABVD

Hazard Ratio (95% CI)

no. of events/total no. (%)
Overall
Age
<60 yr
≥60 yr
<65 yr
≥65 yr
<45 yr
≥45 yr
Geographic region
Americas
North America
Europe
Asia
IPS
0–1
2–3
4–7
Baseline Ann Arbor stage
Stage III
Stage IV
Baseline B symptoms
Yes
No
Baseline extranodal sites
0
1
>1
Baseline ECOG status
0
1
2
Sex
Male
Female

117/664 (17.6)

146/670 (21.8)

0.77 (0.60–0.98)

93/580 (16.0)
24/84 (28.6)
99/604 (16.4)
18/60 (30.0)
70/451 (15.5)
47/213 (22.1)

117/568 (20.6)
29/102 (28.4)
128/608 (21.1)
18/62 (29.0)
83/423 (19.6)
63/247 (25.5)

0.73 (0.56–0.96)
1.00 (0.58–1.72)
0.74 (0.57–0.96)
1.01 (0.53–1.94)
0.73 (0.53–1.01)
0.86 (0.59–1.25)

41/261 (15.7)
38/250 (15.2)
62/333 (18.6)
14/70 (20.0)

58/262 (22.1)
57/247 (23.1)
74/336 (22.0)
14/72 (19.4)

0.65 (0.44–0.97)
0.60 (0.40–0.90)
0.83 (0.59–1.17)
0.91 (0.43–1.94)

22/141 (15.6)
57/354 (16.1)
38/169 (22.5)

25/141 (17.7)
68/351 (19.4)
53/178 (29.8)

0.84 (0.47–1.49)
0.79 (0.55–1.12)
0.70 (0.46–1.07)

40/237 (16.9)
77/425 (18.1)

43/246 (17.5)
102/421 (24.2)

0.92 (0.60–1.42)
0.71 (0.53–0.96)

77/400 (19.3)
40/264 (15.2)

94/381 (24.7)
52/289 (18.0)

0.74 (0.55–1.01)
0.79 (0.52–1.20)

40/217 (18.4)
36/217 (16.6)
39/194 (20.1)

39/228 (17.1)
45/223 (20.2)
57/193 (29.5)

1.04 (0.67–1.62)
0.75 (0.48–1.16)
0.67 (0.44–1.00)

61/376 (16.2)
48/260 (18.5)
8/28 (28.6)

79/378 (20.9)
57/263 (21.7)
10/27 (37.0)

0.74 (0.53–1.03)
0.83 (0.56–1.21)
0.54 (0.21–1.38)

64/378 (16.9)
53/286 (18.5)

90/398 (22.6)
56/272 (20.6)

0.70 (0.51–0.97)
0.86 (0.59–1.26)
0.5

0.1

A+AVD
Better

1.0

ABVD
Better

Figure 2. Forest-Plot Analysis of Modified Progression-free Survival.
This forest plot shows modified progression-free survival according to the independent review committee in key prespecified subgroups.
The hazard ratio for treatment with A+AVD versus ABVD and the 95% confidence intervals (CIs) were based on an unstratified Cox
proportional-hazards regression model, with treatment as the explanatory variable. The intention-to-treat population included all the
patients who underwent randomization. The International Prognostic Score (IPS) ranges from 0 to 7, with higher scores indicating increased risk of treatment failure: low risk, 0 or 1; intermediate risk, 2 or 3; and high risk, 4 to 7. The Ann Arbor staging system ranges
from I to IV, with higher stages indicating more widespread disease. B symptoms consist of night sweats, unexplained fever (temperature >38°C), or loss of more than 10% of body weight. Values for the Eastern Cooperative Oncology Group (ECOG) performance status
range from 0 to 5, with higher scores indicating greater disability.

These subgroups included patients from North
America, patients with involvement of more than
one extranodal site, patients with an IPS indicating a high risk of treatment failure (scores of
4 to 7), men, patients with stage IV disease, and
patients younger than 60 years of age. The rates
of negativity at PET2 (Deauville score, 1 to 3)
were 89% with A+AVD versus 86% with ABVD.
There were 28 deaths in the A+AVD group
n engl j med 378;4

(9 during treatment [within 30 days after the last
dose of frontline therapy] and 19 during followup [31 days or more after the last dose of frontline therapy]) and 39 deaths in the ABVD group
(13 during treatment and 26 during follow-up).
The interim 2-year overall survival rate for the
A+AVD group was 96.6% (95% CI, 94.8 to 97.7)
and that for the ABVD group was 94.2% (95%
CI, 92.0 to 95.9), which corresponded to a reduc-
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tion in the risk of death of 27% in favor of the
A+AVD regimen (hazard ratio, 0.73; 95% CI, 0.45
to 1.18; P = 0.20) (Fig. S2 in the Supplementary
Appendix). Results for other secondary end
points are shown in Table 3. Only 15 of 662
patients who received A+AVD and 9 of 659 patients who received ABVD switched to alternative
chemotherapy during frontline therapy for reasons
other than progressive disease (a Deauville score
of 5 in 1 of 15 and 4 of 9 patients, respectively;
adverse events in 12 of 15 and 1 of 9 patients,
respectively; and other reasons in 2 of 15 and 4 of
9 patients, respectively) (Table S5 in the Supplementary Appendix).
Overall, fewer patients in the A+AVD group
than in the ABVD group received subsequent
anticancer therapies. Recipients of these therapies in the A+AVD group versus the ABVD group
were as follows: radiation (in 52 patients in each
group), chemotherapy (66 vs. 99), high-dose
chemotherapy plus transplantation (36 vs. 54),
immunotherapy (10 vs. 16), and chemotherapy
plus radiation (2 vs. 3).
Safety

The median duration of treatment and the number of completed cycles were similar in the two
groups (Table S6 in the Supplementary Appendix). The proportions of patients who received the
regimens as intended, without dose modification
such as delays, holds, or reductions, are shown
in Table S6 in the Supplementary Appendix.
The safety profiles for both groups are summarized in Table 4, and in Table S7 in the Supplementary Appendix. Overall, neutropenia was
reported in 58% of the patients receiving A+AVD
and in 45% of the patients receiving ABVD, and
febrile neutropenia was reported in 19% and
8%, respectively. In both groups, the incidence of
febrile neutropenia was higher among patients
60 years of age or older than among those
younger than 60 years of age (37% vs. 17% in
the A+AVD group and 17% vs. 6% in the ABVD
group). The incidence of febrile neutropenia was
also higher in earlier rather than later cycles of
therapy in both groups (9% in cycle 1 vs. 1 to 6%
in cycles 2 through 6 in the A+AVD group and
4% in cycle 1 vs. ≤1% in cycles 2 through 6 in
the ABVD group). The incidence of discontinuation of any trial drug due to neutropenia or febrile neutropenia was 1% or less in both groups.
The rate of infections (determined in accordance with the MedDRA primary system organ340
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class term of “infections and infestations”) in
the A+AVD group was 55% (361 of 662 patients)
and the rate in the ABVD group was 50% (331
of 659 patients); rates of infection of grade 3 or
higher were 18% (116 of 662 patients) and 10%
(66 of 659 patients), respectively. Discussion with
the independent data and safety monitoring committee (after 75% of enrollment was complete)
led to the recommendation of primary prophylaxis with granulocyte colony-stimulating factor
(G-CSF) for patients who were yet to be enrolled
and who would receive the A+AVD regimen, owing to the higher incidence of febrile neutropenia in that group. In the A+AVD group, the incidence of febrile neutropenia was lower among
the 83 patients who received primary prophylaxis with G-CSF (defined as use of G-CSF by
day 5 of treatment) than among those who did
not (11% [9 of 83] vs. 21% [119 of 579]) (Table 5).
The occurrence of infections and infestations of
grade 3 or higher was also lower among the
patients who received G-CSF than among those
who did not (11% [9 of 83 patients] vs. 18% [107
of 579 patients]).
Peripheral neuropathy (determined on the basis of a standardized MedDRA query; see Table S8
in the Supplementary Appendix) occurred in 67%
of the patients (442 of 662) receiving A+AVD and
43% of the patients (286 of 659) receiving ABVD.
Grade 2 peripheral neuropathy occurred in 20%
of the patients (130 of 662) in the A+AVD group
versus 9% of the patients (57 of 659) in the ABVD
group, and peripheral neuropathy of grade 3 or
higher occurred in 11% of the patients (70 of 662)
in the former group (with grade 4 occurring in
1 patient) versus 2% of the patients (11 of 659) in
the latter. Among patients with peripheral neuropathy, a trial drug was discontinued in 10% in
the A+AVD group (44 of 442) versus 4% in the
ABVD group (11 of 286). Two thirds of the patients in the A+AVD group (295 of 442) who had
peripheral neuropathy had resolution (43%, 191
of 442) or improvement by at least one grade
(24%, 104 of 442) in terms of events related to
peripheral neuropathy at the time of the last
follow-up visit; at that time, 92% of ongoing
events related to peripheral neuropathy were
grade 1 (64%) or grade 2 (29%) in the A+AVD
group. Pulmonary toxicity, defined as events related to interstitial lung disease (in accordance
with a standardized MedDRA query), was reported in 2% of the patients (12 of 662) in the
A+AVD group versus 7% (44 of 659) in the ABVD

nejm.org

January 25, 2018

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on February 8, 2018. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma

group; events of grade 3 or higher were reported
in less than 1% of the patients (5 of 662) in the
former group and 3% of the patients (21 of 659)
in the latter.
During treatment, there were 9 deaths in the
A+AVD group and 13 deaths in the ABVD group.
In the A+AVD group, 7 deaths were associated
with neutropenia (all occurred in patients who
had not received primary prophylaxis with G-CSF
before the onset of neutropenia, with the exception of 1 patient who entered the trial with preexisting neutropenia) and 2 deaths were due to
myocardial infarction. In the ABVD group, 11
deaths were due to or associated with pulmonaryrelated toxicity and 1 death was due to cardiopulmonary failure. The cause of 1 death was
unknown. Among the patients enrolled in the
trial, 37% (242 of 662) in the A+AVD group and
28% (186 of 659) in the ABVD group were hospitalized during the trial.
Fertility was not formally assessed; however,
similar numbers of pregnancies were reported in
each treatment group, which suggests that there
was no significant difference in the effect on
fertility. At the time of this analysis, a total of 78
pregnancies were reported among trial participants and their partners (42 in the A+AVD group
and 36 in the ABVD group).

Discussion

Events

A+AVD
(N = 662)

ABVD
(N = 659)
no. (%)

Adverse events
Any adverse event

653 (99)

646 (98)

Grade ≥3 adverse event

549 (83)

434 (66)

Serious adverse event

284 (43)

178 (27)

88 (13)

105 (16)

9 (1)

13 (2)

Adverse event resulting in drug discontinuation
Death during treatment†
Death due to drug-related adverse events

8 (1)

7 (1)

242 (37)

186 (28)

Any grade

382 (58)

295 (45)

Grade ≥3

357 (54)

260 (39)

Any grade

279 (42)

241 (37)

Grade ≥3

11 (2)

Hospitalizations
Common adverse events‡
Neutropenia

Constipation
4 (<1)

Vomiting
Any grade

216 (33)

183 (28)

Grade ≥3

23 (3)

9 (1)

Any grade

211 (32)

211 (32)

Grade ≥3

19 (3)

7 (1)

Any grade

189 (29)

111 (17)

Grade ≥3

31 (5)

Fatigue

Peripheral sensory neuropathy
3 (<1)

Diarrhea

This large, international, randomized phase 3
trial involving patients who had received a recent
diagnosis of stage III or IV classic Hodgkin’s
lymphoma showed that treatment with brentuximab vedotin plus AVD, as compared with
standard treatment with ABVD, resulted in a
statistically significant and clinically meaningful
improvement in the rate of modified progressionfree survival, with a difference at 2 years of 4.9
percentage points as assessed by an independent
committee, whose members were unaware of
group assignments and 6.6 percentage points as
assessed by the trial investigators. These outcomes were associated with reductions in the
overall risk of failure of the primary chemotherapy treatment of 23% as assessed by an independent review committee and 28% as assessed by the trial investigators.
The goal of frontline chemotherapy for Hodgkin’s lymphoma is to cure patients without the
need for additional therapy. Because metabolically detectable residual disease is a reliable pren engl j med 378;4

Table 4. Summary of Adverse Events in the Safety Population.*

Any grade

181 (27)

Grade ≥3

19 (3)

121 (18)
5 (<1)

Pyrexia
Any grade

179 (27)

147 (22)

Grade ≥3

19 (3)

13 (2)

Any grade

174 (26)

85 (13)

Grade ≥3

27 (4)

6 (<1)

Any grade

142 (21)

65 (10)

Grade ≥3

21 (3)

4 (<1)

Peripheral neuropathy

Abdominal pain

Stomatitis
Any grade

138 (21)

Grade ≥3

10 (2)

104 (16)
3 (<1)

*	For a full summary of adverse events, including rates of drug-related adverse
events and deaths, see Table S7 in the Supplementary Appendix.
†	Death during treatment is a death that occurred within 30 days after the last
dose of frontline therapy.
‡	The events listed include the most clinically important common adverse events.
Adverse events (those of any grade that occurred in at least 20% of the patients
in either group) excluded from the table are nausea, alopecia, weight loss, and
anemia.
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Table 5. Summary of Adverse Events in Patients Who Did and Those Who Did Not Receive Primary Prophylaxis
with Granulocyte Colony-Stimulating Factor.
Events

A+AVD (N = 662)
ABVD (N = 659)
No (N = 579)
Yes (N = 83)
No (N = 616)
Yes (N = 43)
number (percent)

Febrile neutropenia during treatment

119 (21)

9 (11)

49 (8)

3 (7)

Any neutropenia*

425 (73)

29 (35)

352 (57)

9 (21)

Neutropenia grade ≥3*

406 (70)

24 (29)

309 (50)

8 (19)

Grade ≥3 adverse event

502 (87)

47 (57)

414 (67)

20 (47)

Infections and infestations (SOC)

322 (56)

39 (47)

312 (51)

19 (44)

Grade ≥3 infections and infestations (SOC)

107 (18)

9 (11)

63 (10)

3 (7)

Serious adverse event

257 (44)

27 (33)

171 (28)

7 (16)

Serious adverse events of febrile neutropenia,
neutropenia, sepsis, neutropenic sepsis,
pyrexia, or infections and infestations (SOC)

190 (33)

20 (24)

107 (17)

4 (9)

8 (1)

1 (1)‡

12 (2)

1 (2)

Deaths during treatment†

*	Neutropenia and neutropenia grade 3 or higher (neutrophil count <1000 per cubic millimeter) include the preferred
terms of “neutropenia” and “neutrophil count decreased.” SOC denotes system organ class for the noted event.
†	Death during treatment is a death that occurred within 30 days after the last dose of frontline therapy.
‡	The patient in the A+AVD group who had G-CSF primary prophylaxis received G-CSF for treatment of neutropenia,
which occurred before day 5.

dictor of imminent progression, it is accepted
practice to initiate subsequent chemotherapy or
radiotherapy on the basis of a positive PET scan
at the end of frontline treatment.21-23 In this context, the conventional end point of progressionfree survival does not accurately assess the curative intent of frontline chemotherapy. Thus, in
the ECHELON-1 trial, the primary end point was
“modified” progression-free survival, which, in
addition to disease progression or death, included
modified progression, defined as evidence of
noncomplete response after the completion of
frontline chemotherapy (based on independently
assessed PET results) followed by subsequent
anticancer therapy, as an event, thus accurately
assessing the curative potential of the frontline
chemotherapy.
The results of the interim overall survival
analysis and all other secondary efficacy end
points favored A+AVD, further supporting the
conclusion that A+AVD is a more effective frontline treatment for advanced Hodgkin’s lymphoma
than ABVD. Furthermore, the benefit of A+AVD
was observed consistently in the majority of prespecified subgroups, including patients in whom
there was involvement of more than one extranodal site, patients with an IPS indicating high
risk for treatment failure (4 to 7), and patients
with stage IV disease. The rate of positivity at
PET2 was low, and a higher proportion of the
342
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patients treated with A+AVD than those treated
with ABVD had negative results at PET2 (89%
vs. 86%).
This trial shows that the addition of brentuximab vedotin and the elimination of bleomycin
from frontline therapy in the A+AVD regimen
lowers the incidence of pulmonary toxicity while
improving efficacy as compared with the ABVD
regimen. No new types of risk to patient safety
were identified, although the incidence of febrile
neutropenia was higher than expected and an
increased incidence of infections was noted in
the A+AVD group. The majority of the deaths during treatment in the A+AVD group were associated with febrile neutropenia; however, primary
prophylaxis with G-CSF appeared to mitigate
the increased risk of febrile neutropenia and its
sequelae in the subgroup of 83 patients who received primary prophylaxis, resulting in reduced
rates of neutropenia, febrile neutropenia, and serious infection. Peripheral neuropathy occurred
more frequently in patients in the A+AVD group.
The incidence of peripheral neuropathy of grade
3 or higher was increased by 9 percentage points
in this group as compared with the ABVD group,
and peripheral neuropathy was largely reversible,
either resolving or abating in 67% of the patients
in whom the condition had developed. Both the
percentage of patients who received subsequent
salvage chemotherapy and the percentage of pa-
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tients who received high-dose chemotherapy followed by transplantation were approximately 33%
lower among patients treated with A+AVD than
among patients treated with ABVD; those treated with A+AVD were therefore less likely to be
subject to the toxicities associated with aggressive salvage therapies.
The results of the ECHELON-1 trial are particularly important considering the opportunity
A+AVD provides to administer a treatment to
older patients that is at least equivalent in its
effectiveness to ABVD, and to do so safely. Older
patients with advanced Hodgkin’s lymphoma represent a special group, considering their incidence
of disease (approximately 20% of all cases),
lower rates of treatment efficacy, and typically
higher rates of severe toxicity, particularly the
pulmonary toxicity that is associated with bleomycin.6,24,25 When choosing frontline treatment,
it is important to consider the lifetime burden of
late and long-term adverse effects from salvage
chemotherapy, radiotherapy, and transplantation
(including infertility, pulmonary and cardiac toxicities, and secondary cancers).26,27 The A+AVD
regimen is associated with more myelotoxicity
(which can be ameliorated with prophylactic
G-CSF) and neurotoxicity (which is largely reversible) than ABVD but substantially less pulmonary toxicity and appears to be more effective
for the frontline treatment of advanced-stage
classic Hodgkin’s lymphoma.
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